Targeting Six1/Eya2 for fibrosis

靶向 Six1/Eya2 治疗纤维化

• 批准号: 10255325
• 负责人: Juan Marugan
• 金额: $ 11.24万
• 依托单位: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10255325
• 关键词: Chronic; Collaborations; Disease; Drug Kinetics; Environmental Risk Factor; Fibrosis; Genetic; Goals; Inflammation; Modeling; Process; Research; Signal Transduction; Testing; Tissues; Transforming Growth Factor beta; Translations; design; epithelial to mesenchymal transition; inhibitor/antagonist; response; small molecule; small molecule therapeutics; therapeutic development; transcription factor; wound healing

During this period, the collaborative team has developed a research plan to assess Six1-Eya2 disruptors in a model of fibrosis. Pharmacokinetic studies have been designed to determine exposure levels in relevant tissues. The Early Translation Branch's (ETB) overall goal is to uncover new small molecule therapeutics and catalyze the process of therapeutic development through a model of collaborative research. Within this collaboration, the team will test the hypothesis that Six1-Eya2 disruptors will diminish fibrosis.

在此期间，合作团队制定了一项研究计划，以评估纤维化模型中的SIX1-Eya2干扰物。药代动力学研究旨在确定相关组织中的暴露水平。 早期翻译部(ETB)的总体目标是发现新的小分子疗法，并通过合作研究的模式催化治疗开发的进程。在这项合作中，该团队将测试SIX1-Eya2干扰物将减少纤维化的假设。